The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Biomarker Development

2014 ACR/ARHP Annual Meeting: Biomarker Development

February 1, 2015 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Biomarker Development

BOSTON—Speakers at the ACR/ARHP Annual Meeting in Boston in November 2014 highlighted proteomic and metabolomic research during a session called Advances in Molecular Profiling and Relevance to Autoimmune Disease. Advances in the research point to a role for proteomic-based profiling in rheumatologic diseases for biomarker development and help clarify a relationship of metabolomics with autoimmune and rheumatic disease.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Alive and Growing
Explore This Issue
February 2015
Also By This Author
  • ACR/EULAR Response Criteria Approved for Adult, Juvenile Myositis

William H. Robinson, MD, PhD, associate professor of medicine, immunology and rheumatology at Stanford School of Medicine, outlined translational research efforts to identify molecular signatures of disease subtypes that could give rise to next-generation biomarkers to guide clinical decision making. The research is using “composite signaling profiles to identify pathogenic mechanisms in RA,” Dr. Robinson said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Genomics & proteomics can tell you what might happen, but metabolomics tells you what actually did happen.

Research has shown that RA-related autoantibodies develop years prior to clinical onset of RA, but the initial antigen targets and how these antibodies develop are not well understood. In studies conducted by Dr. Robinson and colleagues, researchers found that autoantibodies target several innate immune ligands at early time points before clinical RA develops.1 The targeted ligands include citrullinated histones, fibrinogen, and biglycan. Expansion of the anticitrullinated protein antibody (ACPA) predicted elevations in inflammatory cytokines, including TNF-α, IL-6, IL-12p70 and IFN-γ. Their findings indicate that the preclinical phase of RA is characterized by an accumulation of multiple autoantibody specificities reflecting the process of epitope spread. This epitope spread is also correlated with development of preclinical inflammation, thus providing a biomarker profile that could predict imminent onset of clinical arthritis, he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Role of Citrullinated Proteins

Research by Drs. Robinson, Jeremy Sokolove and colleagues published in 2013 showed that citrullinated proteins are present within atherosclerotic plaque and that RA-associated autoantibodies can target the protein in atherosclerotic plaque tissue.2 Those findings provided a foundation for future studies investigating the role of ACPA as a contributor to the accelerated atherosclerosis observed in patients with RA.

The production of autoantibodies, including ACPAs, is a defining factor in RA, but targets of these antibodies are not clearly defined. B cells that are specific for the inciting antigens are activated during an immune response and differentiate into plasmablasts that are released into the blood. Dr. Robinson and colleagues3 published research in 2014 that described efforts to sequence the plasmablast antibody repertoire to define the targets of active immune response in RA. Using a novel DNA barcoding method, they showed that autoantibodies targeting α-enolase, citrullinated fibrinogen and citrullinated histone H2B are produced by ongoing activated B cell response in RA and may contribute to the pathogenesis of RA, Dr. Robinson said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: AC&R, Annual Meeting, Association of Rheumatology Professionals (ARP), Biomarker, Holliman, molecular, ResearchIssue: February 2015

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Alive and Growing
  • The 2014 ACR/ARHP Annual Meeting Must-See Pre-Meeting Courses

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)